{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:09:18Z","timestamp":1775700558069,"version":"3.50.1"},"reference-count":42,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage \u2265\u2009IIB mycosis fungoides), S\u00e9zary syndrome, gamma\/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (n\u2009=\u200948), S\u00e9zary syndrome (n\u2009=\u200928) or aggressive non-mycosis fungoides\/S\u00e9zary syndrome subtypes (n\u2009=\u20099). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides\/S\u00e9zary syndrome identified age \u2265\u200970 years, Eastern Cooperative Oncology Group Performance\u00a0Status \u2265\u2009\u20092, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides\/ S\u00e9zary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16\u2013101 months.<\/jats:p>","DOI":"10.2340\/actadv.v102.1087","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:45:42Z","timestamp":1643265942000},"page":"adv00676","source":"Crossref","is-referenced-by-count":5,"title":["Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas"],"prefix":"10.2340","volume":"102","author":[{"given":"Jos\u00e9phine","family":"Franceschi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Visseaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Durlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Barbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Durot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"16862","doi-asserted-by":"crossref","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.","DOI":"10.1182\/blood-2004-09-3502"},{"key":"16863","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2004-09-3502","DOI":"10.1182\/blood-2004-09-3502"},{"key":"16864","doi-asserted-by":"crossref","unstructured":"Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240-1251.","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"16865","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jnci\/92.15.1240","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"16866","doi-asserted-by":"crossref","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-5073.","DOI":"10.1182\/blood-2008-10-184168"},{"key":"16867","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2008-10-184168","DOI":"10.1182\/blood-2008-10-184168"},{"key":"16868","doi-asserted-by":"crossref","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.","DOI":"10.1182\/blood-2007-03-055749"},{"key":"16869","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2007-03-055749","DOI":"10.1182\/blood-2007-03-055749"},{"key":"16870","doi-asserted-by":"crossref","unstructured":"Mourad A, Gniadecki R. Overall survival in mycosis fungoides: a systematic review and meta-analysis. J Invest Dermatol 2020; 140: 495-497.","DOI":"10.1016\/j.jid.2019.07.712"},{"key":"16871","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2019.07.712","DOI":"10.1016\/j.jid.2019.07.712"},{"key":"16872","doi-asserted-by":"crossref","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium Study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol Off J Am Soc Clin Oncol 2015; 33: 3766-3773.","DOI":"10.1200\/JCO.2015.61.7142"},{"key":"16873","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2015.61.7142","DOI":"10.1200\/JCO.2015.61.7142"},{"key":"16874","doi-asserted-by":"crossref","unstructured":"Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now? Br J Dermatol 2014; 170: 1226-1236.","DOI":"10.1111\/bjd.12909"},{"key":"16875","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12909","DOI":"10.1111\/bjd.12909"},{"key":"16876","doi-asserted-by":"crossref","unstructured":"Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer Oxf Engl 1990 2013; 49: 2859-2868.","DOI":"10.1016\/j.ejca.2013.04.018"},{"key":"16877","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2013.04.018","DOI":"10.1016\/j.ejca.2013.04.018"},{"key":"16878","doi-asserted-by":"crossref","unstructured":"Laban \u00c9, Beylot-Barry M, Ortonne N, Battistella M, Carlotti A, de Muret A, et al. Lymphoprolif\u00e9rations cutan\u00e9es: proposition d'algorithmes diagnostiques \u00e0 partir de l'exp\u00e9rience sur 2 ans des r\u00e9seaux INCa (LYMPHOPATH et GFELC) sur 2760 lymphoprolif\u00e9rations cutan\u00e9es. Ann Pathol 2015; 35: 131-147.","DOI":"10.1016\/j.annpat.2015.02.001"},{"key":"16879","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annpat.2015.02.001","DOI":"10.1016\/j.annpat.2015.02.001"},{"key":"16880","unstructured":"Grange F, Hedelin G, Joly P, Beylot-Barry M, D'Incan M, Delaunay M, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the S\u00e9zary syndrome. The French Study Group on Cutaneous Lymphomas. Blood 1999; 93: 3637-3642."},{"key":"16881","doi-asserted-by":"crossref","unstructured":"Bouaziz J-D, Bastuji-Garin S, Poszepczynska-Guign\u00e9 E, Wechsler J, Bagot M. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol 2006; 154: 1206-1207.","DOI":"10.1111\/j.1365-2133.2006.07264.x"},{"key":"16882","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07264.x","DOI":"10.1111\/j.1365-2133.2006.07264.x"},{"key":"16883","doi-asserted-by":"crossref","unstructured":"Beylot-Barry M, Vergier B, Masquelier B, Bagot M, Joly P, Souteyrand P, et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23: 1208-1216.","DOI":"10.1097\/00000478-199910000-00005"},{"key":"16884","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/00000478-199910000-00005","DOI":"10.1097\/00000478-199910000-00005"},{"key":"16885","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"16886","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2016-01-643569","DOI":"10.1182\/blood-2016-01-643569"},{"key":"16887","doi-asserted-by":"crossref","unstructured":"Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.","DOI":"10.1182\/blood-2006-10-054601"},{"key":"16888","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2006-10-054601","DOI":"10.1182\/blood-2006-10-054601"},{"key":"16889","unstructured":"Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988; 132: 265-277."},{"key":"16890","doi-asserted-by":"crossref","unstructured":"Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-425.","DOI":"10.1016\/S0190-9622(99)70491-3"},{"key":"16891","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(99)70491-3","DOI":"10.1016\/S0190-9622(99)70491-3"},{"key":"16892","doi-asserted-by":"crossref","unstructured":"Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051-5060.","DOI":"10.1158\/1078-0432.CCR-12-0604"},{"key":"16893","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0604","DOI":"10.1158\/1078-0432.CCR-12-0604"},{"key":"16894","doi-asserted-by":"crossref","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-866.","DOI":"10.1001\/archderm.139.7.857"},{"key":"16895","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.139.7.857","DOI":"10.1001\/archderm.139.7.857"},{"key":"16896","doi-asserted-by":"crossref","unstructured":"Nikolaou V, Papadavid E, Patsatsi A, Siakantaris M, Economidi A, Marinos L, et al. Prognostic indicators for mycosis fungoides in a Greek population. Br J Dermatol 2017; 176: 1321-1330.","DOI":"10.1111\/bjd.15000"},{"key":"16897","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15000","DOI":"10.1111\/bjd.15000"},{"key":"16898","doi-asserted-by":"crossref","unstructured":"Danish HH, Liu S, Jhaveri J, Flowers CR, Lechowicz MJ, Esiashvili N, et al. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and S\u00e9zary syndrome. Leuk Lymphoma 2016; 57: 2813-2819.","DOI":"10.3109\/10428194.2016.1173210"},{"key":"16899","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/10428194.2016.1173210","DOI":"10.3109\/10428194.2016.1173210"},{"key":"16900","doi-asserted-by":"crossref","unstructured":"Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"16901","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2456","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"16902","doi-asserted-by":"crossref","unstructured":"Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672-684.","DOI":"10.1067\/mjd.2002.124607"},{"key":"16903","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2002.124607","DOI":"10.1067\/mjd.2002.124607"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1087\/3239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1087\/3240","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1087\/3239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:18:12Z","timestamp":1655918292000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/1087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":42,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.1087","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,22]]}}}